Marcyrl Pharmaceutical Industries, a leading pharmaceutical manufacturer in Egypt, announced a significant minority investment from DPI and Amethis to enhance access to specialty drugs across Africa.

Information on the Target

Marcyrl Pharmaceutical Industries, founded in 1998, is one of Egypt's top ten pharmaceutical manufacturers renowned for its commitment to enhancing access to specialty generic essential drugs. With a market share exceeding 2% in Egypt, Marcyrl has demonstrated robust growth and resilience in its sales performance. The company prides itself on its ability to innovate and expand its product portfolio, notably in the specialty generic sector.

In particular, Marcyrl has made significant advancements in its offerings since launching its antiviral products for Hepatitis C in 2015. Today, Marcyrl aims to address the critical need for accessible specialty care medications across Africa while leveraging its international export network to facilitate this expansion. The company's ongoing investments in novel therapeutic areas, such as hormonal therapy treatments introduced in 2016, underscore its progressive vision for the future.

Industry Overview in Egypt

The pharmaceutical industry in Egypt is a vibrant sector, contributing substantially to the national economy. With a growing population and increasing disease prevalence, the demand for packaged medicines has reached a valuation of $18 bill